Anumana™ is harnessing industry-leading AI and translational science to decode electrical signals from the heart as never before, empowering healthcare providers to transform patient care throughout the cardiac clinical pathway. Serious cardiovascular diseases affect millions of people worldwide, often going undiagnosed until symptoms advance and patients deteriorate. Unfortunately, these conditions can remain undiagnosed until the patient suffers a life-threatening event. Innovations enabling earlier diagnoses could address this unmet medical need and empower healthcare providers to intervene with life-saving treatments. Anumana’s 100+ peer-reviewed publications and ongoing research show significant promise to detect and diagnose otherwise hidden conditions earlier and uncover actionable insights for valuable patient interventions. The opportunity to offer clinical decision support tools for each unique patient throughout the cardiac care continuum paves the way for precision medicine. Anumana strives to introduce a new standard of care in cardiac clinical care supported by reimbursement.
| Website | http://anumana.ai |
| Employees | 153 (136 on RocketReach) |
| Founded | 2021 |
| Industry | Medical Equipment Manufacturing |
| Competitors | PathAI, Tempus Labs, Inc., IBM, Flatiron Health, Verily, Arterys, Aidoc, Freenome, Health Catalyst, Medial EarlySign +38 more (view full list) |
Looking for a particular Anumana employee's phone or email?
Maulik Nanavaty is the CEO of Anumana.
136 people are employed at Anumana.